Targeting α7 nicotinic acetylcholine receptors： a future potential for neuroprotection from traumatic brain injury

Traumatic brain injury （TBI） poses a significant socioeconomic burden in the world. The long lasting consequences in cognitive impairments are often underreported and its mechanisms are unclear. In this perspective, cholinergic dysfunction and thera-peutic strategy targeting this will be reviewed. N...

Full description

Saved in:
Bibliographic Details
Published inNeural regeneration research Vol. 10; no. 10; pp. 1552 - 1554
Main Authors Shin, Samuel S, Dixon, C Edward
Format Journal Article
LanguageEnglish
Published India Medknow Publications & Media Pvt. Ltd 01.10.2015
Department of Neurological Surgery,University of Pittsburgh Medical Center,Pittsburgh,PA,USA
Medknow Publications & Media Pvt Ltd
Wolters Kluwer Medknow Publications
Subjects
Animal cognition
Brain research
Clinical trials
Cognitive ability
Highlights
Ligands
Memory
Nervous system
Permeability
Schizophrenia
Signal transduction
SSR
Traumatic brain injury
创伤性脑损伤
功能障碍
烟碱型乙酰胆碱受体
社会经济
神经保护作用
胆碱能
认知障碍
@@
Online AccessGet full text

Cover

More Information
Summary:Traumatic brain injury （TBI） poses a significant socioeconomic burden in the world. The long lasting consequences in cognitive impairments are often underreported and its mechanisms are unclear. In this perspective, cholinergic dysfunction and thera-peutic strategy targeting this will be reviewed. Novel agents that can target specific subtype of acetylcholine receptors have been developed over the recent years and are at various stages of development, which include AR-R 17779, GTS-21, SSR- 180711A, AR-R17779, and PNU-282987. A detailed review on this topic has been previously published （Shin and Dixon, 2015）.
Bibliography:Traumatic brain injury （TBI） poses a significant socioeconomic burden in the world. The long lasting consequences in cognitive impairments are often underreported and its mechanisms are unclear. In this perspective, cholinergic dysfunction and thera-peutic strategy targeting this will be reviewed. Novel agents that can target specific subtype of acetylcholine receptors have been developed over the recent years and are at various stages of development, which include AR-R 17779, GTS-21, SSR- 180711A, AR-R17779, and PNU-282987. A detailed review on this topic has been previously published （Shin and Dixon, 2015）.
11-5422/R
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1673-5374
1876-7958
DOI:10.4103/1673-5374.165309